-
1
-
-
0034685403
-
Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)
-
ALLHAT COLLABORATIVE RESEARCH GROUP
-
ALLHAT COLLABORATIVE RESEARCH GROUP: Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA (2000) 283:1967-1975.
-
(2000)
JAMA
, vol.283
, pp. 1967-1975
-
-
-
2
-
-
0345967847
-
Impact of clinical trials results on national trends in α-blocker prescribing, 1996-2002
-
STAFFORD RS, FURBERG CJ, FINDKELSTEIN SN et al.: Impact of clinical trials results on national trends in α-blocker prescribing, 1996-2002. JAMA (2004) 291:54-62.
-
(2004)
JAMA
, vol.291
, pp. 54-62
-
-
Stafford, R.S.1
Furberg, C.J.2
Findkelstein, S.N.3
-
3
-
-
0030579074
-
The α-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate
-
HETANO A, TANG R, WALDEN PD, LEPOR H: The α-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate. Eur. J. Pharmacol. (1996) 313:135-143.
-
(1996)
Eur. J. Pharmacol.
, vol.313
, pp. 135-143
-
-
Hetano, A.1
Tang, R.2
Walden, P.D.3
Lepor, H.4
-
4
-
-
0035148442
-
α-Blockade downregulates myosin heavy chain gene expression in human benign prostatic hyperplasia
-
LIN VK, BENAIM EA, MCCONNELL JD: α-Blockade downregulates myosin heavy chain gene expression in human benign prostatic hyperplasia. Urology (2001) 57:170-175.
-
(2001)
Urology
, vol.57
, pp. 170-175
-
-
Lin, V.K.1
Benaim, E.A.2
Mcconnell, J.D.3
-
5
-
-
0032861498
-
α1-Adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia
-
CHON JK, BORKOWSKI A, PARTIN AW et al.: α1-Adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J. Urol. (1999) 161:2002-2008.
-
(1999)
J. Urol.
, vol.161
, pp. 2002-2008
-
-
Chon, J.K.1
Borkowski, A.2
Partin, A.W.3
-
6
-
-
0032426688
-
Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia
-
KYPRIANOU N, LITVAK JP, BORBOWSKI A, ALEXANDER R, JACOBS SC: Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J. Urol. (1998) 159:1810-1815.
-
(1998)
J. Urol.
, vol.159
, pp. 1810-1815
-
-
Kyprianou, N.1
Litvak, J.P.2
Borbowski, A.3
Alexander, R.4
Jacobs, S.C.5
-
11
-
-
0036328850
-
Effect of doxazosin on stretch-activated adenosine triphosphate release in bladder urothelial cells from patients with benign prostatic hyperplasia
-
SUN Y, MALOSSI J, JACOBS SC, CHAI TC: Effect of doxazosin on stretch-activated adenosine triphosphate release in bladder urothelial cells from patients with benign prostatic hyperplasia. Urology (2002) 60:351-356.
-
(2002)
Urology
, vol.60
, pp. 351-356
-
-
Sun, Y.1
Malossi, J.2
Jacobs, S.C.3
Chai, T.C.4
-
12
-
-
0032923005
-
Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia
-
FAWZY A, VASHI V, CHUNG M et al.: Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Urology (1999) 53:329-335.
-
(1999)
Urology
, vol.53
, pp. 329-335
-
-
Fawzy, A.1
Vashi, V.2
Chung, M.3
-
13
-
-
0032749958
-
Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation
-
CHUNG M, VASHI V, PUENTE J, SWEENEY M, MEREDITH P: Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br. J. Clin. Pharmacol. (1999) 48:678-687.
-
(1999)
Br. J. Clin. Pharmacol.
, vol.48
, pp. 678-687
-
-
Chung, M.1
Vashi, V.2
Puente, J.3
Sweeney, M.4
Meredith, P.5
-
14
-
-
0027502569
-
Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study
-
CHRISTENSEN MM, BENDIX HOLME J, RASMUSSEN PC et al.: Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand. J. Urol. Nephrol. (1993) 27:39-44.
-
(1993)
Scand. J. Urol. Nephrol.
, vol.27
, pp. 39-44
-
-
Christensen, M.M.1
Bendix Holme, J.2
Rasmussen, P.C.3
-
15
-
-
0028206741
-
29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study
-
BENDIX HOLME J, CHRISTENSEN MM, RASMUSSEN PC et al.: 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. Scand. J. Urol. Nephrol. (1994) 28:77-82.
-
(1994)
Scand. J. Urol. Nephrol.
, vol.28
, pp. 77-82
-
-
Bendix Holme, J.1
Christensen, M.M.2
Rasmussen, P.C.3
-
16
-
-
0028285327
-
A three month double-blind study of doxazosin as treatment of benign prostatic bladder outlet obstruction
-
CHAPPLE CR, CARTER P, CHRISTMAS TJ et al.: A three month double-blind study of doxazosin as treatment of benign prostatic bladder outlet obstruction. Br. J. Urol. (1994) 74:50-56.
-
(1994)
Br. J. Urol.
, vol.74
, pp. 50-56
-
-
Chapple, C.R.1
Carter, P.2
Christmas, T.J.3
-
17
-
-
0029002126
-
Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study
-
FAWZY A, BRAUN K, LEWIS GP et al.: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J. Urol. (1995) 154:105-109.
-
(1995)
J. Urol.
, vol.154
, pp. 105-109
-
-
Fawzy, A.1
Braun, K.2
Lewis, G.P.3
-
18
-
-
0029024313
-
Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled, dose-response multicenter study
-
GILLENWATER JY, CONN RL, CHRYSANT SG et al.: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J. Urol. (1995) 154:110-115.
-
(1995)
J. Urol.
, vol.154
, pp. 110-115
-
-
Gillenwater, J.Y.1
Conn, R.L.2
Chrysant, S.G.3
-
19
-
-
0028805836
-
Doxazosin in benign prostatic hyperplasia: Effects on blood pressure and urinary flow in normotensive and hypertensive men
-
KIRBY RS: Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology (1995) 46:182-186.
-
(1995)
Urology
, vol.46
, pp. 182-186
-
-
Kirby, R.S.1
-
20
-
-
0030248565
-
Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies
-
ROEHRBORN CG, SIEGEL RL: Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology (1996) 48:406-415.
-
(1996)
Urology
, vol.48
, pp. 406-415
-
-
Roehrborn, C.G.1
Siegel, R.L.2
-
21
-
-
0031021415
-
Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients
-
The Multicenter Study Group
-
LEPOR H, KAPLAN SA, KLIMBERG I et al.: Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J. Urol. (1997) 157:525-530.
-
(1997)
J. Urol.
, vol.157
, pp. 525-530
-
-
Lepor, H.1
Kaplan, S.A.2
Klimberg, I.3
-
22
-
-
0031749908
-
Tolerability of α-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: A pooled analysis of seven double-blind, placebo-controlled studies
-
KAPLAN SA, D'ALISERA PM: Tolerability of α-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies. J. Gerontol, A Biol. Sci. Med. Sci. (1998) 53:M201-M206.
-
(1998)
J. Gerontol. A Biol. Sci. Med. Sci.
, vol.53
-
-
Kaplan, S.A.1
D'alisera, P.M.2
-
23
-
-
0032851611
-
A randomized double-blind study assessing 4 versus 8 mg doxazosin for benign prostatic hyperplasia
-
MACDIARMID SA, EMERY RT, FERGUSON SF: A randomized double-blind study assessing 4 versus 8 mg doxazosin for benign prostatic hyperplasia. J. Urol. (1999) 162:1629-1632.
-
(1999)
J. Urol.
, vol.162
, pp. 1629-1632
-
-
Macdiarmid, S.A.1
Emery, R.T.2
Ferguson, S.F.3
-
24
-
-
0029554501
-
Doxazosin in physiological and pharmacologically normotensive men with benign prostatic hyperplasia
-
KAPLAN SA, MEADE-D'ALISERA P, QUINONES S, SOLDO KA: Doxazosin in physiological and pharmacologically normotensive men with benign prostatic hyperplasia. Urology (1995) 146:512-517.
-
(1995)
Urology
, vol.146
, pp. 512-517
-
-
Kaplan, S.A.1
Meade-D'alisera, P.2
Quinones, S.3
Soldo, K.A.4
-
25
-
-
18244387257
-
Observational multicentric trial performed with doxazosin: Evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia
-
DEROSE AF, CARMIGNANI G, CORBU C: Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol. Int. (2002) 68:95-98.
-
(2002)
Urol. Int.
, vol.68
, pp. 95-98
-
-
Derose, A.F.1
Carmignani, G.2
Corbu, C.3
-
26
-
-
0033755524
-
Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia
-
ANDERSEN M, DAHLSTRAND C, HOYE K: Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur. Urol. (2000) 38:400-409.
-
(2000)
Eur. Urol.
, vol.38
, pp. 400-409
-
-
Andersen, M.1
Dahlstrand, C.2
Hoye, K.3
-
27
-
-
0034612429
-
Doxazosin GITS versus regular doxazosin in benign prostatic hyperplasia. Restoring urine flow and sexual function more easily
-
GRATZKE P, KIRBY RS: [Doxazosin GITS versus regular doxazosin in benign prostatic hyperplasia. Restoring urine flow and sexual function more easily]. MMW Fortschr Med. (2000) 142(26-27):40.
-
(2000)
MMW Fortschr Med.
, vol.142
, Issue.26-27
, pp. 40
-
-
Gratzke, P.1
Kirby, R.S.2
-
28
-
-
0035122753
-
A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia
-
KIRBY RS, ANDERSEN R, GRATZKE P, DAHLSTRAND C, HOYE K: A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. Br. J. Urol. Int. (2001) 87:192-200.
-
(2001)
Br. J. Urol. Int.
, vol.87
, pp. 192-200
-
-
Kirby, R.S.1
Andersen, R.2
Gratzke, P.3
Dahlstrand, C.4
Hoye, K.5
-
29
-
-
0036820774
-
Present and future pharmacotherapy for benign prostatic hyperplasia
-
DOGGRELL SA: Present and future pharmacotherapy for benign prostatic hyperplasia. Future Drugs (2002) 27:973-986.
-
(2002)
Future Drugs
, vol.27
, pp. 973-986
-
-
Doggrell, S.A.1
-
30
-
-
0035104828
-
Discontinuation of α-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction
-
BALDWIN KC, GINSBERG PC, HARKAWAY RC: Discontinuation of α-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. Urol. Int. (2001) 66:84-88.
-
(2001)
Urol. Int.
, vol.66
, pp. 84-88
-
-
Baldwin, K.C.1
Ginsberg, P.C.2
Harkaway, R.C.3
-
31
-
-
0034899266
-
Discontinuation of α-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia
-
BALDWIN KC, GINSBERG PC, ROEHRBORN CG, HARKAWAY RC: Discontinuation of α-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology (2001) 58:203-209.
-
(2001)
Urology
, vol.58
, pp. 203-209
-
-
Baldwin, K.C.1
Ginsberg, P.C.2
Roehrborn, C.G.3
Harkaway, R.C.4
-
32
-
-
0037253614
-
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial
-
KIRBY RS, ROEHRBORN C, BOYLE P et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology (2003) 61:119-126.
-
(2003)
Urology
, vol.61
, pp. 119-126
-
-
Kirby, R.S.1
Roehrborn, C.2
Boyle, P.3
-
33
-
-
0030249241
-
Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
-
BOYLE P, GOULD AL, ROEHRBORN CG: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology (1996) 48:396-405.
-
(1996)
Urology
, vol.48
, pp. 396-405
-
-
Boyle, P.1
Gould, A.L.2
Roehrborn, C.G.3
-
34
-
-
0347882750
-
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
-
MCCONNEL JD, ROEHRBORN CG, BAUTISTA OM et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. (2003) 349:2387-2398.
-
(2003)
N. Engl. J. Med.
, vol.349
, pp. 2387-2398
-
-
Mcconnel, J.D.1
Roehrborn, C.G.2
Bautista, O.M.3
-
35
-
-
0037232329
-
A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia
-
KIRKBY RS: A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. Br. J. Urol. Int. (2003) 91:41-44.
-
(2003)
Br. J. Urol. Int.
, vol.91
, pp. 41-44
-
-
Kirkby, R.S.1
-
36
-
-
1942446146
-
Comparative efficacy of two α-adrenoceptor antagonists doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement
-
DE REIJKE TM, KLARSKOV P: Comparative efficacy of two α-adrenoceptor antagonists doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. Br. J. Urol. Int. (2004) 93:757-762.
-
(2004)
Br. J. Urol. Int.
, vol.93
, pp. 757-762
-
-
De Reijke, T.M.1
Klarskov, P.2
-
37
-
-
0035702786
-
Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: Decreased expression of heat shock proteins
-
HOOPER PL: Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins. Curr. Control Trials Cardiovasc. Med. (2001) 2:251-253.
-
(2001)
Curr. Control Trials Cardiovasc. Med.
, vol.2
, pp. 251-253
-
-
Hooper, P.L.1
|